September 20th 2024
Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
New Biomarker May Help Detect Metastatic Endometrial Cancer
March 17th 2017We spoke with Dr. G. Larry Maxwell, Chair of the Department of Obstetrics and Gynecology at Inova Fairfax Hospital, about a potential new biomarker to help distinguish metastatic versus nonmetastatic disease in endometrial cancer.
Maintenance Chemo After CR Fails to Extend Survival in Ovarian Cancer
March 14th 2017A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.
Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma
March 14th 2017Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.
Reduced, Compressed Chemotherapy Fails in Pediatric Germ Cell Tumors
March 11th 2017Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.
Genetic Analysis May Offer New Approach to Treating Ovarian Cancer
February 21st 2017California researchers are now suggesting that analyzing copies of genes may point to new treatments for ovarian cancer as well as for other tumor types. The researchers contend that targetable genetic changes in tumors should not be limited to mutations.
BRCA Reversion Mutations in cfDNA Can Predict Response in Ovarian Cancer
February 14th 2017A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA in patients with recurrent high-grade serous ovarian cancer. Those reversion mutations can help predict poor response to therapy in these patients.